TG Therapeutics 配当と自社株買い

配当金基準チェック /06

TG Therapeutics配当金を支払った記録がありません。

主要情報

n/a

配当利回り

0.04%

バイバック利回り

総株主利回り	0.04%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

Nov 07

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

Nov 05

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Sep 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Aug 09

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

May 29

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

May 04

TG Therapeutics: Less Room For Doubt About Briumvi

May 03

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

May 03

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Mar 25

TG Therapeutics: Briumvi Growth Story Appears Intact

Mar 01

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Mar 01

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Jan 10

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Jan 04

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Nov 24

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Sep 30

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Aug 03

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Jul 19

Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?

Apr 13

Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?

Jan 02

TG Therapeutics: Elucidating The Upcoming Binary

Oct 09

TG Therapeutics: We Are Just Hanging In There

Sep 21

決済の安定と成長

配当データの取得

安定した配当: TGTXの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: TGTXの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

TG Therapeutics 配当利回り対市場

TGTX 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (TGTX)	n/a
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Biotechs)	2.3%
アナリスト予想 (TGTX) (最長3年)	0%

注目すべき配当: TGTXは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。

高配当: TGTXは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。

株主への利益配当

収益カバレッジ: TGTXの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: TGTXが配当金を報告していないため、配当金の持続可能性を計算できません。

TG Therapeutics 配当と自社株買い

配当金 基準チェック /06

主要情報

最近の配当と自社株買いの更新

Recent updates

Independent Director recently sold US$490k worth of stock

Independent Director notifies of intention to sell stock

Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking

TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.34 loss in 2Q 2023)

Price target increased by 8.6% to US$36.67

Investor sentiment improves as stock rises 15%

TG Therapeutics, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Price target increased by 8.3% to US$34.25

TG Therapeutics, Inc. Announces Updated Data Presentations Including New Five-Year Data from ULTIMATE I & II Phase 3 Trials Evaluating BRIUMVI (Ublituximab-Xiiy) in Patients with Relapsing Forms of Multiple Sclerosis

TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry

Investor sentiment improves as stock rises 16%

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

TG Therapeutics Receives U.S. Food and Drug Administration Clearance for Its Investigational New Drug (IND) Application

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback

TG Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates upgraded to US$0.019 loss

Independent Director recently sold US$433k worth of stock

Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission

CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics

Hold TG Therapeutics For Intriguing Outcomes

TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement

Investor sentiment improves as stock rises 26%

TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates

TG Therapeutics: Less Room For Doubt About Briumvi

News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Price target increased by 15% to US$34.14

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

TG Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Consensus EPS estimates fall by 42%, revenue upgraded

TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet

Lead Independent Director recently sold US$351k worth of stock

Consensus EPS estimates fall by 24%

TG Therapeutics: Briumvi Growth Story Appears Intact

Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 11% to US$32.57

Price target increased by 10% to US$32.43

TG Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Price target increased by 9.2% to US$29.07

Forecast breakeven date pushed back to 2024

TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference

Price target increased by 11% to US$29.44

CFO, Corporate Secretary & Treasurer recently sold US$809k worth of stock

CFO, Corporate Secretary & Treasurer notifies of intention to sell stock

Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S

Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

TG Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Price target decreased by 9.1% to US$25.06

Consensus EPS estimates upgraded to US$0.57 loss, revenue downgraded

Forecast breakeven date pushed back to 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar

Consensus EPS estimates fall by 24%

Chairman recently bought US$1.0m worth of stock

New major risk - Financial position

No longer forecast to breakeven

Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts

Price target decreased by 8.4% to US$29.06

TG Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Consensus revenue estimates increase by 11%

Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?

Independent Director recently sold US$815k worth of stock

Forecast breakeven date moved forward to 2024

Independent Director notifies of intention to sell stock

CFO, Corporate Secretary & Treasurer recently sold US$2.0m worth of stock

CFO, Corporate Secretary & Treasurer notifies of intention to sell stock

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Tg Therapeutics Announces European Commission Approval for Briumvi (Ublituximab-Xiiy) for the Treatment of Relapsing Forms of Multiple Sclerosis in Adults

Consensus revenue estimates increase by 25%

Price target increased by 43% to US$33.31

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

配当金基準チェック /06